Key result
Compared to olanzapine, chlorpromazine and haloperidol were associated with higher risks of sudden cardiac death and ventricular arrhythmia, while quetiapine had lower risk.
Why the study?
Does the choice of antipsychotic affect the risk of sudden cardiac death, ventricular arrhythmia, and all-cause death in incident antipsychotic users?
Cohort (n=459,614)
Yes
Does the choice of antipsychotic affect the risk of sudden cardiac death, ventricular arrhythmia, and all-cause death in incident antipsychotic users?
Haloperidol and chlorpromazine are associated with higher risks of sudden cardiac death and ventricular arrhythmia compared to olanzapine, while quetiapine is associated with a lower risk, suggesting average QT prolongation is a poor surrogate for arrhythmogenicity.
Answers are grounded in this paper and cite their sources.
Certain antipsychotics may raise SD/VA risk versus others; leaves open causal effects and optimal selection.
CONTEXT: Antipsychotic drugs have been linked to QT-interval prolongation, a presumed marker of cardiac risk, and torsade de pointes. OBJECTIVE: To examine the associations between antipsychotics and 1) outpatient-originated sudden cardiac death and ventricular arrhythmia (SD/VA) and 2) all-cause death. DESIGN: Two retrospective cohort studies. SETTING: Medicaid programs of California, Florida, New York, Ohio and Pennsylvania. PATIENTS: Incident antipsychotic users aged 30-75 years. MAIN OUTCOME MEASURES: 1) Incident, first-listed emergency department or principal inpatient SD/VA diagnoses; and 2) death reported in the Social Security Administration Death Master File. RESULTS: Among 459,614 incident antipsychotic users, the incidences of SD/VA and death were 3.4 and 35.1 per 1,000 person-years, respectively. Compared to olanzapine as the referent, adjusted hazard ratios (HRs) for SD/VA were 2.06 (95% CI, 1.20-3.53) for chlorpromazine, 1.72 (1.28-2.31) for haloperidol, and 0.73 (0.57-0.93) for quetiapine. Adjusted HRs for perphenazine and risperidone were consistent with unity. In a subanalysis limited to first prescription exposures, HRs for chlorpromazine and haloperidol were further elevated (2.54 [1.07-5.99] and 2.68 [1.59-4.53], respectively), with the latter exhibiting a dose-response relationship. Results for death were similar. CONCLUSIONS: Haloperidol and chlorpromazine had less favorable cardiac safety profiles than olanzapine. Among atypical agents, risperidone had a similar cardiac safety profile to olanzapine, whereas quetiapine was associated with 30% and 20% lower risks of SD/VA and death, respectively, compared to olanzapine. These measured risks do not correlate well with average QT prolongation, further supporting the notion that average QT prolongation may be a poor surrogate of antipsychotic arrhythmogenicity.
No takes yet. Share an insight, caveat, or question.
Charles E. Leonard (2012) conducted a cohort in Incident antipsychotic users (n=459,614). Antipsychotics (chlorpromazine, haloperidol, quetiapine, perphenazine, risperidone) vs. Olanzapine was evaluated on Incident, first-listed emergency department or principal inpatient sudden cardiac death and ventricular arrhythmia (SD/VA) diagnoses (HR 2.06, 95% CI 1.20-3.53). Compared to olanzapine, chlorpromazine and haloperidol were associated with higher risks of sudden cardiac death and ventricular arrhythmia, while quetiapine had lower risk.
Synapse has enriched 10 related papers. Consider them for comparative context: